These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

753 related items for PubMed ID: 19572644

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Sequence, structure, and active site analyses of p38 MAP kinase: exploiting DFG-out conformation as a strategy to design new type II leads.
    Badrinarayan P, Sastry GN.
    J Chem Inf Model; 2011 Jan 24; 51(1):115-29. PubMed ID: 21141877
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Pyrazolo-pyrimidines: a novel heterocyclic scaffold for potent and selective p38 alpha inhibitors.
    Das J, Moquin RV, Pitt S, Zhang R, Shen DR, McIntyre KW, Gillooly K, Doweyko AM, Sack JS, Zhang H, Kiefer SE, Kish K, McKinnon M, Barrish JC, Dodd JH, Schieven GL, Leftheris K.
    Bioorg Med Chem Lett; 2008 Apr 15; 18(8):2652-7. PubMed ID: 18359226
    [Abstract] [Full Text] [Related]

  • 11. Discovery and characterization of a substrate selective p38alpha inhibitor.
    Davidson W, Frego L, Peet GW, Kroe RR, Labadia ME, Lukas SM, Snow RJ, Jakes S, Grygon CA, Pargellis C, Werneburg BG.
    Biochemistry; 2004 Sep 21; 43(37):11658-71. PubMed ID: 15362850
    [Abstract] [Full Text] [Related]

  • 12. Biphenyl amide p38 kinase inhibitors 1: Discovery and binding mode.
    Angell RM, Bamborough P, Cleasby A, Cockerill SG, Jones KL, Mooney CJ, Somers DO, Walker AL.
    Bioorg Med Chem Lett; 2008 Jan 01; 18(1):318-23. PubMed ID: 18006306
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Switch control pocket inhibitors of p38-MAP kinase. Durable type II inhibitors that do not require binding into the canonical ATP hinge region.
    Ahn YM, Clare M, Ensinger CL, Hood MM, Lord JW, Lu WP, Miller DF, Patt WC, Smith BD, Vogeti L, Kaufman MD, Petillo PA, Wise SC, Abendroth J, Chun L, Clark R, Feese M, Kim H, Stewart L, Flynn DL.
    Bioorg Med Chem Lett; 2010 Oct 01; 20(19):5793-8. PubMed ID: 20800479
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Biochemical and biophysical characterization of unique switch pocket inhibitors of p38α.
    Swann SL, Merta PJ, Kifle L, Groebe D, Sarris K, Hajduk PJ, Sun C.
    Bioorg Med Chem Lett; 2010 Oct 01; 20(19):5787-92. PubMed ID: 20471255
    [Abstract] [Full Text] [Related]

  • 20. Analysis of c-Met kinase domain complexes: a new specific catalytic site receptor model for defining binding modes of ATP-competitive ligands.
    Asses Y, Leroux V, Tairi-Kellou S, Dono R, Maina F, Maigret B.
    Chem Biol Drug Des; 2009 Dec 01; 74(6):560-70. PubMed ID: 19909299
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.